Rafferty Asset Management, LLC Blueprint Medicines Corp Transaction History

Rafferty Asset Management, LLC

$28.9 Billion
Q3 2024

A detailed history of Rafferty Asset Management, LLC transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Rafferty Asset Management, LLC holds 117,024 shares of BPMC stock, worth $13 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares

117,024

Previous 94,963 23.23%

Holding current value

$13 Million

Previous $10.2 Million 5.72%

% of portfolio

0.04%

Previous 0.04%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$84.1 - $120.5 $1.86 Million - $2.66 Million	22,061 Added 23.23%	117,024 $10.8 Million
Q2 2024 Aug 13, 2024	SELL	$85.18 - $108.78 $373,769 - $477,326	-4,388 Reduced 4.42%	94,963 $10.2 Million
Q1 2024 May 13, 2024	SELL	$73.17 - $99.79 $1.61 Million - $2.2 Million	-22,017 Reduced 18.14%	99,351 $9.42 Million
Q4 2023 Feb 13, 2024	SELL	$43.96 - $92.84 $1.99 Million - $4.21 Million	-45,322 Reduced 27.19%	121,368 $11.2 Million
Q3 2023 Nov 13, 2023	BUY	$46.9 - $66.0 $1.16 Million - $1.63 Million	24,693 Added 17.39%	166,690 $8.37 Million
Q2 2023 Aug 11, 2023	SELL	$42.2 - $66.37 $839,484 - $1.32 Million	-19,893 Reduced 12.29%	141,997 $8.97 Million
Q1 2023 May 11, 2023	SELL	$37.97 - $50.0 $333,832 - $439,600	-8,792 Reduced 5.15%	161,890 $7.28 Million
Q4 2022 Feb 13, 2023	BUY	$41.06 - $66.48 $3.27 Million - $5.29 Million	79,592 Added 87.38%	170,682 $7.48 Million
Q3 2022 Nov 14, 2022	BUY	$49.93 - $77.7 $583,531 - $908,079	11,687 Added 14.72%	91,090 $6 Million
Q2 2022 Aug 12, 2022	SELL	$45.23 - $70.15 $643,713 - $998,374	-14,232 Reduced 15.2%	79,403 $4.01 Million
Q1 2022 May 13, 2022	BUY	$54.1 - $110.08 $2.12 Million - $4.32 Million	39,214 Added 72.06%	93,635 $5.98 Million
Q4 2021 Feb 10, 2022	BUY	$94.25 - $115.99 $2.15 Million - $2.65 Million	22,836 Added 72.3%	54,421 $5.83 Million
Q3 2021 Nov 10, 2021	BUY	$80.98 - $109.47 $127,219 - $171,977	1,571 Added 5.23%	31,585 $3.25 Million
Q2 2021 Aug 10, 2021	SELL	$82.78 - $101.0 $85,511 - $104,333	-1,033 Reduced 3.33%	30,014 $2.64 Million
Q1 2021 May 10, 2021	BUY	$90.71 - $108.28 $2.08 Million - $2.48 Million	22,919 Added 281.98%	31,047 $3.02 Million
Q4 2020 Feb 10, 2021	SELL	$92.08 - $124.48 $2 Million - $2.7 Million	-21,730 Reduced 72.78%	8,128 $912,000
Q3 2020 Nov 13, 2020	BUY	$66.45 - $92.7 $1.08 Million - $1.5 Million	16,194 Added 118.52%	29,858 $2.77 Million
Q2 2020 Aug 07, 2020	BUY	$57.09 - $79.27 $474,360 - $658,654	8,309 Added 155.16%	13,664 $1.07 Million
Q1 2020 May 15, 2020	SELL	$48.11 - $82.22 $1.93 Million - $3.3 Million	-40,170 Reduced 88.24%	5,355 $313,000
Q4 2019 Feb 10, 2020	SELL	$66.73 - $82.59 $2.44 Million - $3.02 Million	-36,595 Reduced 44.56%	45,525 $3.65 Million
Q3 2019 Nov 14, 2019	BUY	$72.9 - $101.41 $2.01 Million - $2.8 Million	27,608 Added 50.65%	82,120 $6.03 Million
Q2 2019 Aug 09, 2019	BUY	$73.54 - $97.8 $1.34 Million - $1.78 Million	18,182 Added 50.05%	54,512 $5.14 Million
Q1 2019 May 15, 2019	BUY	$48.7 - $86.6 $1.77 Million - $3.15 Million	36,330 New	36,330 $2.91 Million

Others Institutions Holding BPMC

# of Institutions

350

Shares Held

60.3M

Call Options Held

2.25M

Put Options Held

1.18M

View Full List

About Blueprint Medicines Corp

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $6.63B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

More about BPMC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rafferty Asset Management, LLC with notifications on news.

Account

Rafferty Asset Management, LLC Blueprint Medicines Corp Transaction History